Login to Your Account

FDA Committee Wants More Data For MT 100 In Migraine

By Aaron Lorenzo

Friday, August 5, 2005
ROCKVILLE, Md. - Prospects are growing dim for MT 100, a migraine drug developed by Pozen Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription